Frazier Healthcare Ventures in Seattle continues to bolster its life sciences investment team.
Last week, Frazier announced that Julian Nikolchev and Michael Gallatin have joined as venture partners. Nikolchev has two decades of experience in the medical device industry and was previously founder and president of CardioMind Inc., a VC-backed developer of a guidewire-based stent delivery system. Gallatin is the former chief scientific officer of ICOS Corp. (Nasdaq: ICOS), the developer of Cialis and other products.
Separately, Frazier also promoted Steven Tallman from entrepreneur-in-residence to venture partner. Tallman joined the firm in 1999. Frazier says that he was instrumental in much of the early due and development of Calypso Medical Technologies, a medical device company that targets cancer, and which has raised more than $80 million in VC financing from Frazier and other investors.
Frazier is currently investing from its fifth health care fund, a $475 million vehicle raised in 2004.